| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.linkpharmachem.co.in | |
| Market Cap | 19.38 Cr. | |
| Enterprise Value(EV) | 26.07 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -4.09 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.99 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 30.09 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 1.45 | Calculated using Price: 43.64 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 0.44 Cr. | 4,440,568 Shares |
| FaceValue | 10 | |
| About Link Pharma Chem Ltd. | ||
| Link Pharma Chem, incorporated on December 28, 1984 is a manufacturer of thionyl chloride. | ||
| 1 Day |
|
-0.96% |
| 1 Week |
|
+3.56% |
| 1 Month |
|
+5.48% |
| 3 Month |
|
-6.57% |
| 6 Month |
|
+0.61% |
| 1 Year |
|
+13.15% |
| 2 Year |
|
-19.09% |
| 5 Year |
|
+111.90% |
| 10 Year |
|
+781.19% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | -23.07 | 6.83 | 2.58 | 12.34 | 6.53 | 8.71 | 9.04 | 13.92 | 4.43 | |
| Return on Capital Employed (%) | -8.74 | 9.83 | 9.26 | 15.38 | 10.31 | 12.87 | 13.58 | 16.57 | 7.38 | |
| Return on Assets (%) | -8.35 | 2.7 | 1.31 | 6.61 | 3.74 | 5.14 | 4.82 | 6.84 | 2.13 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 8 | 9 | 9 | 10 | 10 | 11 | 13 | 14 | 15 | 13 | |
| Non Curr. Liab. | 8 | 1 | 2 | 3 | 3 | 4 | 4 | 4 | 3 | 2 | |
| Curr. Liab. | 9 | 7 | 7 | 4 | 5 | 3 | 9 | 11 | 15 | 13 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 26 | 18 | 17 | 17 | 18 | 19 | 26 | 29 | 32 | 27 | |
| Non Curr. Assets | 18 | 10 | 10 | 11 | 11 | 10 | 11 | 15 | 15 | 14 | |
| Curr. Assets | 8 | 7 | 7 | 7 | 7 | 9 | 15 | 14 | 18 | 14 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 26 | 18 | 17 | 17 | 18 | 19 | 26 | 29 | 32 | 27 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 18 | 12 | 16 | 24 | 25 | 25 | 35 | 54 | 39 | 31 | |
| Other Income | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | |
| Total Income | 18 | 15 | 16 | 24 | 25 | 26 | 35 | 54 | 39 | 32 | |
| Total Expenditure | -18 | -13 | -14 | -21 | -22 | -23 | -32 | -50 | -36 | -32 | |
| PBIDT | -1 | 3 | 2 | 3 | 2 | 3 | 3 | 4 | 3 | -1 | |
| Interest | -1 | -1 | -1 | -1 | 0 | 0 | 0 | 0 | -1 | -1 | |
| Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Taxation | 1 | 0 | 0 | 0 | 0 | 0 | -1 | -1 | 0 | 1 | |
| Exceptional Items | |||||||||||
| PAT | -2 | 1 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | -2 | |
| Adjusted EPS | -5 | 1 | 1 | 3 | 1 | 2 | 2 | 4 | 1 | -4 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 1 | 5 | -4 | 2 | 4 | 1 | 3 | 5 | -1 | -2 | |
| Cash Fr. Inv. | -1 | -3 | 9 | -1 | -1 | -1 | -2 | -2 | -5 | 0 | |
| Cash Fr. Finan. | 0 | -1 | -6 | -1 | -3 | 0 | 1 | 0 | 2 | 2 | |
| Net Change | 0 | 1 | -1 | 0 | 0 | 2 | 2 | -4 | 0 | ||
| Cash & Cash Eqvt | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 4 | 0 | 0 |
|
Tue, 23 Apr 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation regarding issue of " Letter of Confirmation" in lieu of lost share certificate under Regulation 30(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Sat, 20 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Khushbu Prakashbhai Patel Designation: Company Secretary and Compliance Officer EmailId: linkpharmacs@gmail.com Name of the Chief Financial Officer: Sanjib Ranjit Dutta Designation: Chief Financial Officer EmailId: acc.linkpharmaltd@gmail.com Date: 20/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Sat, 20 Apr 2024
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.
Date: 20/04/2024 |
||||||||||||||||||||||||||||||||||||||||||||||||||
| Fri, 26 Apr 2024 |
High Delivery Percentage
|
High Increase in 5 Years
|
CCI Trending Down
|
RSI Trending Down
|
ROC Trending Down
|
